CA2955441C - Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 - Google Patents

Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 Download PDF

Info

Publication number
CA2955441C
CA2955441C CA2955441A CA2955441A CA2955441C CA 2955441 C CA2955441 C CA 2955441C CA 2955441 A CA2955441 A CA 2955441A CA 2955441 A CA2955441 A CA 2955441A CA 2955441 C CA2955441 C CA 2955441C
Authority
CA
Canada
Prior art keywords
compound
cancer
disclosed
independently
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2955441A
Other languages
English (en)
Other versions
CA2955441A1 (fr
Inventor
Larry Schlesinger
Eric BACHELDER
Fred COPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardinal Health 414 LLC
Ohio State Innovation Foundation
Original Assignee
Cardinal Health 414 LLC
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardinal Health 414 LLC, Ohio State Innovation Foundation filed Critical Cardinal Health 414 LLC
Publication of CA2955441A1 publication Critical patent/CA2955441A1/fr
Application granted granted Critical
Publication of CA2955441C publication Critical patent/CA2955441C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des composés et des compositions pour cibler les macrophages et autres cellules à expression élevée de CD206.
CA2955441A 2014-07-17 2015-07-17 Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 Active CA2955441C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462025991P 2014-07-17 2014-07-17
US62/025,991 2014-07-17
US201462027193P 2014-07-21 2014-07-21
US201462027220P 2014-07-21 2014-07-21
US62/027,193 2014-07-21
US62/027,220 2014-07-21
US201462027733P 2014-07-22 2014-07-22
US62/027,733 2014-07-22
PCT/US2015/041019 WO2016011419A1 (fr) 2014-07-17 2015-07-17 Compositions pour le ciblage de macrophages et autres cellules à expression élevée de cd206 et méthodes de traitement et de diagnostic

Publications (2)

Publication Number Publication Date
CA2955441A1 CA2955441A1 (fr) 2016-01-21
CA2955441C true CA2955441C (fr) 2023-03-14

Family

ID=55079110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2955441A Active CA2955441C (fr) 2014-07-17 2015-07-17 Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296

Country Status (3)

Country Link
EP (1) EP3169336A4 (fr)
CA (1) CA2955441C (fr)
WO (1) WO2016011419A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
WO2016011415A2 (fr) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Composés et compositions pour cibler des macrophages et d'autres cellules exprimant, avec un fort niveau d'expression, les récepteurs lectines de type c liant le mannose, ainsi que méthodes de traitement et de diagnostic faisant appel à ceux-ci
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA3039519A1 (fr) * 2016-10-04 2018-04-12 Cardinal Health 414, Llc Compositions et methodes de diagnostic et de traitement de troubles lies aux macrophages au moyen d'un support macromoleculaire a base de glucides
MX2019004033A (es) * 2016-10-07 2019-12-05 Navidea Biopharmaceuticals Inc Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos.
EP3655107A4 (fr) * 2017-07-21 2021-04-28 Navidea Biopharmaceuticals, Inc. Utilisation de 99mtc-tilmanocept et de constructions moléculaires associées pour l'identification et le diagnostic de tumeurs malignes, et pour le suivi d'interventions thérapeutiques antitumorales
CN112840211A (zh) * 2018-08-27 2021-05-25 南特生物公司 Rp182组合物及方法
MX2021011703A (es) * 2019-03-27 2022-01-06 Navidea Biopharmaceuticals Inc Composiciones y métodos para alterar el fenotipo de macrófagos.
CN115151264B (zh) * 2019-09-30 2024-03-12 纳维迪亚生物制药有限公司 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
US11859023B2 (en) 2020-07-08 2024-01-02 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
WO2023150695A1 (fr) 2022-02-04 2023-08-10 Navidea Biopharmaceuticals, Inc. Modification de la charge nette sur des dextranes mannosylés pour maximiser l'absorption tissulaire cible et le blocage compétitif cible

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069820A (en) * 1965-12-21 1967-05-24 Akad Wissenschaften Ddr Tuberculostatic compounds
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
WO2012169973A1 (fr) * 2011-06-09 2012-12-13 Agency For Science, Technology And Research Nanoparticule à cœur-écorce
WO2016011415A2 (fr) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Composés et compositions pour cibler des macrophages et d'autres cellules exprimant, avec un fort niveau d'expression, les récepteurs lectines de type c liant le mannose, ainsi que méthodes de traitement et de diagnostic faisant appel à ceux-ci

Also Published As

Publication number Publication date
EP3169336A4 (fr) 2018-04-04
CA2955441A1 (fr) 2016-01-21
EP3169336A1 (fr) 2017-05-24
WO2016011419A1 (fr) 2016-01-21

Similar Documents

Publication Publication Date Title
US20230218783A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CA2955441C (fr) Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296
US20220211680A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US11020493B2 (en) Double-labeled probe for molecular imaging and use thereof
US10806803B2 (en) Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
JP7449864B2 (ja) エバンスブルー誘導体の化学結合体ならびに前立腺癌を標的とするための放射線療法および造影剤としてのその使用
US20190022259A1 (en) Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
US20210338827A1 (en) Compounds and methods for diagnosis and treatment of viral infections
JP2021504453A (ja) 分子イメージングのための二重標識プローブ及びその使用
JP2021502399A (ja) 分子イメージングのための二重標識プローブ及びその使用
US11542267B2 (en) Cryptate compounds
US20170202969A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US11497763B1 (en) Compounds and methods for treating and diagnosing RNA virus infections
US20240009314A1 (en) Compositions and methods for targeting tumor-associated macrophages

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714